The DOI matches its Crossref record; 73 of the 81 references it cites were found in a registry or an index; 27 of the 67 sources its claims cite were checked for support.
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial
Open accessAbstract
Phase 2a multicenter, double-blind, randomized, placebo-controlled trial of rentosertib (formerly ISM001-055), a first-in-class AI-generated small-molecule inhibitor of TNIK for idiopathic pulmonary fibrosis. Safety was similar across arms; highest-dose group showed mean FVC increase versus decline with placebo over 12 weeks.
Overview
CoChat Summary
## TL;DR
This phase 2a randomized, double-blind, placebo-controlled trial found that the AI-discovered TNIK inhibitor rentosertib was generally safe and well tolerated in idiopathic pulmonary fibrosis (IPF) over 12 weeks. The highest dose tested, 60 mg once daily, showed the most favorable lung-function signal, including a mean FVC change of +98.4 ml versus −20.3 ml with placebo.
## Key findings
- Among 71 randomized patients, treatment-emergent adverse events were common but similar across groups: 72.2% (13/18) with 30 mg QD, 83.3% (15/18) with 30 mg BID, 83.3% (15/18) with 60 mg QD, and 70.6% (12/17) with placebo.
- Treatment-related serious adverse events were uncommon: 0 in placebo, 1/18 (5.6%) in 30 mg QD, and 2/18 (11.1%) in each of the 30 mg BID and 60 mg QD groups.
- After 12 weeks, mean FVC change was −20.3 ml with placebo, −27.0 ml with 30 mg QD, +19.7 ml with 30 mg BID, and +98.4 ml with 60 mg QD (95% CI 10.9 to 185.9).
- In the 60 mg QD group without concurrent standard-of-care antifibrotic therapy, FVC improved by +187.8 ml (95% CI 68.6 to 306.9 ml); the paper also reports a significant LCQ improvement at 60 mg QD versus placebo (two-sided P = 0.0495).
## Methods
- Phase 2a, multicenter, double-blind, randomized, placebo-controlled, multidose trial at 21 sites in China; adults with IPF were assigned 1:1:1:1 to placebo or rentosertib 30 mg QD, 30 mg BID, or 60 mg QD for 12 weeks.
- 128 patients were screened and 71 enrolled; the intention-to-treat population included all 71 randomized patients, and all were included in safety and efficacy analyses.
- Primary endpoint was the proportion with at least one treatment-emergent adverse event; secondary analyses included FVC and other lung-function measures, LCQ, 6MWD, pharmacokinetics, and exploratory serum proteomics, using ANCOVA for FVC, mixed models for LCQ, multiple imputation for missing week-12 values, and generalized linear/mixed models for proteomics.
## Limitations
- The paper states that limitations include the small cohort size in each arm, the geographical and demographic homogeneity of participants (all residents of China of similar race), and the short follow-up period, which limit assessment of long-term safety and efficacy.
- The text makes evident that 22/71 patients were missing week-12 measurements and 16/71 (22.5%) discontinued treatment before study end, which may affect precision and completeness of efficacy estimates.
- The 12-week duration is also explicitly noted as relatively short for capturing longer-term events such as acute exacerbations of IPF.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
20 Valid · 2 Not valid · 13 Not checked · 70 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Despite substantial progress in artificial intelligence (AI) for generative chemistry, few novel AI-discovered or AI-designed drugs have reached human clinical trials.”
- Also stated in: § Main · plain
“Despite these advancements, few AI-discovered or AI-designed drugs have reached clinical trials.”
§ A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial > Abstract Despite substantial progress in artificial intelligence (AI) for generative chemistry, few novel AI-discovered or AI-designed drugs have reached human clinical trials. Here we present the results of the first phase 2a multicenter, double-blind, randomized, placebo-controlled trial testing the safety and efficacy of rentosertib (formerly ISM001-055), a first-in-class AI-generated small-molecule inhibitor of TNIK, a first-in-class target in idiopathic pulmonary fibrosis (IPF) discovered using generative AI. IPF is an age-related progressive lung condition with no current therapies available that reverse the degenerative course of disease. Patients were randomized to 12 weeks of treatment with 30 mg rentosertib once daily (QD, n = 18), 30 mg rentosertib twice daily (BID, n = 18), 60 mg rentosertib QD (n = 18) or placebo (n = 17). The primary endpoint was the percentage of patients who have at least one treatment-emergent adverse event, which was similar across all treatment arms (72.2% in patients receiving 30 mg rentosertib QD (n = 13/18), 83.3% for 30 mg rentosertib BID (n = 15/18), 83.3% for 60 mg rentosertib QD (n = 15/18) and 70.6% for placebo (n = 12/17)). Treatment-related serious adverse event rates were low and comparable across treatment groups, with the most common events leading to treatment discontinuation related to liver toxicity or diarrhea. Secondary endpoints included pharmacokinetic dynamics (Cmax, Ctrough, tmax, AUC0–t/τ/∞ and t1/2), changes in lung function as measured by forced vital capacity, diffusion capacity of the lung for carbon monoxide, forced expiry in 1 s and change in the Leicester Cough Questionnaire score, change in 6-min walk distance and the number and hospitalization duration of acute exacerbations of IPF. We observed increased forced vital capacity at the highest dosage with a mean change of +98.4 ml (95% confidence interval 10.9 to 185.9) for patients in the 60 mg rentosertib QD group, compared with −20.3 ml (95% confidence interval −116.1 to 75.6) for the placebo group. These results suggest that targeting TNIK with rentosertib is safe and well tolerated and warrants further investigation in larger-scale clinical trials of longer duration. ClinicalTrials.gov registration number: NCT05938920.
What the sources say
- Could not verifycites [20] Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273–286 (2019). sourceExperimental — accuracy not yet measured
The Introduction describes a dataset of clinical trials involving more than 21,000 compounds, but does not identify which, if any, were AI-discovered or AI-designed. Searches for AI-designed drugs and generative chemistry found no passage addressing how many such drugs reached human trials. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [21] KP Jayatunga, M., Ayers, M., Bruens, L., Jayanth, D. & Meier, C. How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug Discov. Today 29, 104009 (2024). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Main · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“however, a 12-week study is a relatively short time frame to capture such long-term disease events or trajectory44.”
§ A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial > Discussion
What the sources say
- Supportedcites [44] Richeldi, L. et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N. Engl. J. Med. 386, 2178–2187 (2022). source
The Discussion identifies the 12-week duration as a limitation. It says the trial was long enough to assess changes in FVC but too short, given its size, to meaningfully collect data on clinically important events such as acute exacerbations or death. This supports the claim about longer-term events or disease trajectory. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Pathway enrichment analysis identified extracellular matrix organization as the most downregulated Reactome pathway gene set in both treatment groups,”
- Also stated in: § Post-hoc exploratory analyses · plain
“Pathway enrichment analysis identified extracellular matrix organization as the most downregulated Reactome pathway gene set in both treatment groups”
§ A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial > Results > Post-hoc exploratory analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Post-hoc exploratory analyses · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this phase 2a study, treatment with rentosertib at 30 mg QD, 30 mg BID and 60 mg QD over 12 weeks was safe and well tolerated.”
§ A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial > Discussion
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients who received 30 mg rentosertib QD showed a similar mean reduction in FVC of −27.0 ml (95% CI −88.8 to 34.8)”
§ A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial > Results > Secondary lung function endpoints
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
33 more claims
Create a free account to see all 105 claims and to verify the 12 references still open.
- It may state two separate claims as one. 42
- Probably not a substantial claim. 36
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“AI has also facilitated the identification of new targets, including the kinase TNIK, and the design of senomorphic molecules capable of suppressing the SASP129,130.”
From Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming (2026) · cites this paper as [129]
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Graham, B. L., Steenbruggen, I., Miller, M. R., Barjaktarevic, I. Z., Cooper, B. G., Hall, G. L., Hallstrand, T. S., Kaminsky, D. A., McCarthy, K., McCormack, M. C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1590st · Cited by 4,305 · cited 2×
“%) had FVC and FEV1 measured at baseline/randomization with centrally sourced Spiro-Sphere devices (Clario) provided by the sponsor with study-specific training and proficiency tests to the operating staff to meet the 2019 ATS/ERS guideline criteria 63 with central overread.”
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103 · cited 1×
“…of interstitial lung disease (for example, environmental exposures, connective tissue disease, hypersensitivity pneumonitis or drug toxicities) 24 and marked by interstitial pneumonia, dyspnea and cough 25 , histologically characterized by fibroblast proliferation and extracellular matrix…”
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Standardization of Spirometry — 1987 Update
Buist, A. S. (1987) · American Review of Respiratory Disease · doi:10.1164/ajrccm/136.5.1073 · Cited by 3,266
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957 · cited 1×
“Eligible patients were 40 years of age or older with an IPF diagnosis as defined by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Latin American Thoracic Association guidelines 62 .”
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154 · cited 2×
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression 33,34 , as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival 26 , making the development of therapies…”
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“The process of developing novel therapeutics is increasingly slow and costly 1 , with an average of US$2–3 billion spent over the course of 10–15 years to bring a new drug to market 2 .”
Cited by
Leading artificial intelligence–driven drug discovery platforms: 2025 landscape and global outlook
Dharmasivam, M., Kaya, B., Akinware, A., Azad, M. G., & Richardson, D. R. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100102 · Cited by 51
Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 58
Reimagining human-centric drug development with new approach methodologies
Wu, X., Wu, M. A., Zou, J., Kleinstreuer, N., & Wu, J. C. (2026) · Science · doi:10.1126/science.aeb0045 · Cited by 43
Advances in Inhaled Nanoparticle Drug Delivery for Pulmonary Disease Management
Fan, Y., Zhou, Y., Zhao, J., & Zhao, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202502624r · Cited by 43
“Moreover, NCK-interacting kinase (TNIK) as a first- in-class target for IPF and rentosertib as a first- in-class TNIK inhibitor are discovered using AI [191, 192].”
Graph neural networks driven acceleration in drug discovery
Wang, R., & Zhuang, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.011 · Cited by 38
“They successfully screened and targeted a novel and previously 110,113 .”
Metadata
- Authors
- Xu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., Li, H., Liu, H., Luo, F., Meng, Y., Pan, P., Xiang, P., Xiao, Z., Rao, S., Satler, C., Liu, S., Lv, Y., Zhao, H., Chen, S., Cui, H., Korzinkin, M., Gennert, D., & Zhavoronkov, A.
- Affiliations
- Peking Union Medical College Hospital (CN)
- Tianjin Medical University General Hospital (CN)
- Capital Medical University (CN)
- Qilu Hospital of Shandong University (CN)
- Sheng Jing Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- Hainan General Hospital (CN)
- Tongji University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Sichuan University (CN)
- Nanfang Hospital (CN)
- Central South University (CN)
- Peking University Shougang Hospital (CN)
- Jiangxi Provincial People's Hospital (CN)
- Insilico Medicine (United States) (US)
- Corresponding author
- Xu, Zuojun
- Zhavoronkov, Alex
- ORCID
- Venue
- Nature Medicine
- Published
- 2025-06-03
- Volume
- 31
- Issue
- 8
- Pages
- 2602-2610
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC12353801
- OpenAlex
- W4410974018
- Semantic Scholar
- 3a6931210bdb236ad48f646017a88d6faaeb4988
- Cited by
- 180
- References
- 81
- Citations by year
- 2026: 142 · 2025: 38
- FWCI
- 117.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, small molecule inhibitors, lung function, forced vital capacity, pharmacokinetics, safety and tolerability, acute exacerbation, Leicester Cough Questionnaire, 6-minute walk distance, hepatotoxicity, diarrhea, dose comparison
- MeSH terms
- Aged, Artificial Intelligence, Double-Blind Method, Female, Humans, Male, Middle Aged, Treatment Outcome, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. https://app.cochat.ai/papers/10.1038/s41591-025-03743-2
- The paper
- Xu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., Li, H., Liu, H., Luo, F., Meng, Y., Pan, P., Xiang, P., Xiao, Z., Rao, S., Satler, C., . . . Zhavoronkov, A. (2025). A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine. https://doi.org/10.1038/s41591-025-03743-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.